RET regulation and targeting in neuroendocrine prostate cancer
Active Project Grant Awarded Last action
- Award ID
- R01CA269801
- Recipient
-
Regents Of The University Of Minnesota UEI KABJZBBJ4B54
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,838,783
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date 90% complete
- Place of performance
- Minneapolis, MN 55455, USA
Award details come from USAspending.gov.
Description
- Abstract
- Prostate cancer (PCA) is the second leading cause of cancer related death in american men. Typically, treatment for PCA involves blocking androgen synthesis or androgen receptor (AR) signaling known as androgen deprivation therapy (ADT). Although initial response rates are promising, all men eventually progress on ADT and develop castration resistant prostate cancer (crpc) concomitant with metastatic burden. Metastatic crpc is incurable and an increasing number of men are developing a highly lethal variant of crpc known as aggressive variant prostate cancer (avpc). AR signaling is lost in avpc rendering the existing hormone targeting treatments ineffective. About a third of avpc tumors also express neuroendocrine (NE) genes and are classified as neuroendocrine prostate cancer (nepc), which is the focus of our studies. Very few therapies exist and only offer minimal survival benefits in this setting. Hence, functional assessment of other protein drug targets is needed to effectively treat nepc. We have previously shown that kinase signaling pathways may be promising therapeutic alternatives in crpc. The goal of our research is to understand the mechanisms regulating increased kinase gene expression, leading to kinase pathway activation, and how to effectively target these kinases in nepc. Our hypothesis is that RET mrna and protein up-regulation is driven by ASCL1, a master neural transcriptional regulator, and that RET kinase-mediated activity serves as a therapeutic vulnerability in nepc. IT is known that RET mutations are key drivers and therapeutic targets in other cancers with NE features such as papillary thyroid carcinoma and small cell lung cancer. Importantly, the contribution of RET kinase signaling in nepc viability is not entirely elucidated. Our preliminary data shows that RET kinase is overexpressed via activation of a neuronal differentiation transcription factor, ASCL1, and enzymatically activated in mouse models and organoids of nepc, in human cell lines, and clinical nepc tumors. Our work also shows that RET kinase inhibition reduces in vivo xenograft tumor growth and in in vitro mouse organoid models of nepc. The goals of this project are to: 1) confirm ASCL1 as a direct transcriptional regulator of RET, 2) define a RET activity signature and assess the association of this signature to treatment resistance and nepc in clinical samples, and 3) optimize CO-targeting strategies with novel RET inhibitors in nepc model systems. These goals are collectively designed to investigate the mechanism of RET kinase as a key therapeutic target in nepc, an incurable variant of PCA. While kinase inhibitors are approved for treatment of several epithelial cancers, clinical trials of kinase inhibitors in PCA have been disappointing. Our data indicate this is likely due to lack of appropriate patient stratification, administered in the wrong clinical context, and improper combination therapies. Hence, the outcomes of the proposed work will provide new insights into select combination therapies for treating nepc, using RE-purposed kinase inhibitors that may be implemented quickly in clinical trials of patients with this subset of lethal PCA.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $440,732 | |
| Amendment | $44,071 | |
| Amendment | $396,661 | |
| Amendment | $396,661 | |
| Amendment | $418,696 | |
| Amendment | $418,696 | |
| Amendment | $418,696 | |
| Amendment | $431,919 | |
| Amendment | $431,919 | |
| Original award | $440,732 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Collaborative Drug Discovery, Inc. | $45,000 |
Quick answers
Who received award R01CA269801?
R01CA269801 was awarded to Regents Of The University Of Minnesota by National Cancer Institute (National Institutes of Health) on May 1, 2022.
How much is award R01CA269801 worth?
$3,838,783 has been obligated on R01CA269801.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award